Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial)

American Journal of Cardiology

Volumn 107, Issue 6, 2011, Pages 833-840

  Applegate, Robert J ^a   Yaqub, Manejeh ^b   Hermiller, James B ^c   Sood, Poornima ^b   Yu, Shui ^b   Doostzadeh, Julie ^b   Williams, Jerome E ^d   Farhat, Naim ^e   Caputo, Ronald ^f   Lansky, Alexandra J ^h   Cutlip, Donald E ^g   Sudhir, Krishnankutty ^b   Stone, Gregg W ^h  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b ABBOTT VASCULAR   (United States)

^c St Vincent Heart Center of Indiana   (United States)

^d PRESBYTERIAN HOSPITAL   (United States)

^e EMH Regional Medical Center   (United States)

^f St Joseph's Hospital   (United States)

^g HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PACLITAXEL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME; TUBULIN MODULATORS; UNITED STATES;

EID: 79952315876     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.10.069     Document Type: Article

References (20)

1. S. Garg, P. Serruys, Y. Onuma, C. Dorange, S. Veldhof, K. Miquel-Hebert, K. Sudhir, J. Boland, K. Huber, E. Garcia, J.A. te Riele SPIRIT II Investigators 3-Year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 2 2009 1190 1198
2. G.W. Stone, M. Midei, W. Newman, M. Sanz, J.B. Hermiller, J. Williams, N. Farhat, K.W. Mahaffey, D.E. Cutlip, P.J. Fitzgerald, P. Sood, X. Su, A.J. Lansky SPIRIT III Investigators Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
3. G.W. Stone, M. Midei, W. Newman, M. Sanz, J.B. Hermiller, J. Williams, N. Farhat, R. Caputo, N. Xenopoulos, R. Applegate, P. Gordon, R.M. White, K. Sudhir, D.E. Cutlip, J.L. Petersen SPIRIT III Investigators Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial Circulation 119 2009 680 686
4. B.E. Claessen, M.A. Beijk, V. Legrand, W. Ruzyllo, A. Manari, O. Varenne, M.J. Suttorp, J.G.P. Tijssen, K. Miquel-Herbert, S. Veldhof, J.P.S. Henriques, P.W. Serruys, and J.J. Piek Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial Circ Cardiovasc Interv 2 2009 339 347
5. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, G.A. van Es, P.G. Steg, M.A. Morel, L. Mauri, P. Vranckx, E. McFadden, A. Lansky, M. Hamon, M.W. Krucoff, P.W. Serruys Academic Research Consortium Clinical end points in coronary stent trials: A case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
6. A.J. Lansky, G. Dangas, R. Mehran, K.J. Desai, G.S. Mintz, H. Wu, M. Fahy, G.W. Stone, R. Waksman, and M.B. Leon Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation J Am Coll Cardiol 39 2002 274 280 (Pubitemid 34084633)
7. G.S. Mintz, S.E. Nissen, W.D. Anderson, S.R. Bailey, R. Erbel, P.J. Fitzgerald, F.J. Pinto, K. Rosenfield, R.J. Siegel, E.M. Tuzcu, and P.G. Yock American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS) A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 37 2001 1478 1492
8. R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, T. Motta, L. Mihalcsik, M. Tespili, O. Valsecchi, and F.D. Kolodgie Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 109 2004 701 705 (Pubitemid 38222887)
9. E.P. McFadden, E. Stabile, E. Regar, E. Cheneau, A.T.L. Ong, T. Kinnaird, W.O. Suddath, N.J. Weissman, R. Torguson, K.M. Kent, A.D. Pichard, L.F. Satler, R. Waksman, and P.W. Serruys Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 2004 1519 1521 (Pubitemid 39410418)
10. F. Feres, J.R. Costa Jr, and A. Abizaid Very late thrombosis after drug-eluting stents Catheter Cardiovasc Interv 68 2006 83 88 (Pubitemid 44024467)
11. R. Virmani, A. Farb, G. Guagliumi, and F.D. Kolodgie Drug-eluting stents: Caution and concerns for long-term outcome Coron Artery Dis 15 2004 313 318 (Pubitemid 39299245)
12. J. Kotani, M. Awata, S. Nanto, M. Uematsu, F. Oshima, H. Minamiguchi, G.S. Mintz, and S. Nagata Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings J Am Coll Cardiol 47 2006 2108 2111
13. R. Rossini, G. Musumeci, A. Aprile, and O. Valsecchi Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents Expert Rev Pharmacoecon Outcomes Res 10 2010 49 61
14. M. Degertekin, P.W. Serruys, D.P. Foley, K. Tanabe, E. Regar, J. Vos, P.C. Smits, W.J. van der Giessen, M. van den Brand, P. de Feyter, and J.J. Popma Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: Long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up Circulation 106 2002 1610 1613
15. A. Caixeta, M.B. Leon, A.J. Lansky, E. Nikolsky, J. Aoki, J.W. Moses, J. Schofer, M.C. Morice, E. Schampaert, A.J. Kirtane, J.J. Popma, H. Parise, M. Fahy, and R. Mehran 5-year clinical outcomes after sirolimus-eluting stent implantation: Insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents J Am Coll Cardiol 54 2009 894 902
16. S.G. Ellis, G.W. Stone, D.A. Cox, J. Hermiller, C. O'Shaughnessy, T. Mann, M. Turco, R. Caputo, P.J. Bergin, T.S. Bowman, D.S. Baim TAXUS IV Investigators Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: treatment of de novo coronary disease using a single paclitaxel-eluting stent) J Am Coll Cardiol Interv 2 2009 1248 1259
17. G.W. Stone, A. Rizvi, W. Newman, K. Mastali, J.C. Wang, R. Caputo, J. Doostzadeh, S. Cao, C.A. Simonton, K. Sudhir, A.J. Lansky, D.E. Cutlip, D.J. Kereiakes SPIRIT IV Investigators Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
18. C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M.C. Morice, A. Schomig, M.E. Pfisterer, G.W. Stone, M.B. Leon, J.S. de Lezo, J.J. Goy, S.J. Park, M. Sabate, M.J. Suttorp, H. Kelbaek, C. Spaulding, M. Menichelli, P. Vermeersch, M.T. Dirksen, P. Cervinka, M. De Carlo, A. Erglis, T. Chechi, P. Ortolani, M.J. Schalij, P. Diem, B. Meier, S. Windecker, and P. Juni Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis BMJ 337 suppl 2008 a1331
19. E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A.N. DeMaria Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis J Am Coll Cardiol 51 2008 2385 2395 (Pubitemid 351815166)
20. E. Kedhi, K.S. Joesoef, E. McFadden, J. Wassing, C. van Mieghem, D. Goedhart, and P.C. Smits Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209